You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023172013
Dec 20233405
Jan 20242305
Feb 20243802
Mar 20242402
Apr 20243803
May 20242008
Jun 202418011
Jul 20241403
Aug 20242008
Sep 20241204
Oct 20241502
Nov 20243603
Dec 2024809
Jan 20251207
Feb 2025004
Mar 2025004
Apr 2025101
May 2025003
Jun 2025002
Total485099